RxDoctor Payments Data

Peter Wright, MD

Interventional Pain Medicine · Lexington, KYNPI 1477558005

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 5 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Biotronik NRO, Inc. at 34.9% of the total. 2025 is the largest year on record at $81, 5.4 times the $15 reported in 2019. That places this record below the midpoint for interventional pain medicine clinicians in KY, where the typical reported total is $3,169.

$123in general payments, 2019–2025

Across 5 payments — averaging $24.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik NRO, Inc.$43
  • Boston Scientific$27
  • Collegium Pharmaceutical, Inc.$20
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$19
  • MDD US Operations, LLC$15

What the payments were for

  • Food & beverage$123100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$123 in reported general payments places this provider in the 0th percentile of 55 interventional pain medicine providers in Kentucky.

See all interventional pain medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$250,795
Medicare patients
634
Services billed
4,815

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate100$63,417
OxycontinOxycodone Hcl66$56,855
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,873$34,821
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,391$32,207
Oxycodone Hcl1,166$30,914
Fentanyl157$29,895
Gabapentin2,510$27,929
Oxymorphone Hcl ErOxymorphone Hcl35$15,090
Methadone Hcl380$12,574
LyricaPregabalin12$10,741
Morphine Sulfate ErMorphine Sulfate375$9,358
Pregabalin265$7,818
MovantikNaloxegol Oxalate13$5,976
Naloxone Hcl63$4,441
AmantadineAmantadine Hcl19$2,348

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$20$63,417100 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 0th percentile of 55 interventional pain medicine providers in Kentucky.

Other interventional pain medicine in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →